Samrat Pharmachem News

Samrat Pharmachem AGM: FY26 revenue up, EBITDA turns negative

Samrat Pharmachem reported FY26 revenue of ₹289.72 crore, up from ₹285.86 crore. However, EBITDA swung to a loss of ₹3.94 crore from a profit of ₹11.87 crore.

Samrat Pharmachem appoints statutory auditors for 5 years

Samrat Pharmachem Ltd appointed Divyesh J Shah & Associates as statutory auditors for five years, subject to shareholder approval.

Samrat Pharmachem Files FY26 Audited Results in Newspapers

Samrat Pharmachem Limited published an extract of its standalone audited financial results for the quarter and year ended March 31, 2026 in newspapers on June 2, 2026, as required under SEBI LODR Regulation 47.

Samrat Pharmachem Declares Non-Large Corporate Status

Samrat Pharmachem Limited confirms it does not meet SEBI's Large Corporate criteria under circular SEBI/HO/DDHS/CIR/P/2018/144, maintaining compliance with regulatory disclosure requirements.

Samrat Pharmachem Submits Q4FY26 SEBI Certificate

Samrat Pharmachem Limited submitted its quarterly certificate under SEBI Regulation 74(5) for Q4FY26, confirming compliance with dematerialisation requirements through registrar MUFG Intime India.